within Pharmacolibrary.Drugs.ATC.B;

model B01AC18
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.83,
    Cl             = 1.42 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 600 / 1000000,
    adminCount     = 1,
    Vd             = 0.0108,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Triflusal is an antiplatelet agent derived from salicylic acid, used to prevent thromboembolic events in patients at risk of stroke or myocardial infarction, particularly in those with intolerance to acetylsalicylic acid. It acts mainly by inhibiting platelet aggregation. Although once widely used in several countries, it is currently not approved in the United States or many other regions.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers (both sexes), age range 18–64 years.</p><h4>References</h4><ol><li><p>Izquierdo, I, et al., &amp; García-Rafanell, J (2010). Comparative bioavailability study of triflusal oral solution vs. triflusal capsules in healthy subjects. A single, randomized, two-way cross-over, open-label phase I study. <i>Arzneimittel-Forschung</i> 60(1) 36–41. DOI:<a href=&quot;https://doi.org/10.1055/s-0031-1296246&quot;>10.1055/s-0031-1296246</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/20184225/&quot;>https://pubmed.ncbi.nlm.nih.gov/20184225</a></p></li><li><p>Ramis, J, et al., &amp; Jané, F (1991). Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose. <i>European journal of drug metabolism and pharmacokinetics</i> 16(4) 269–273. DOI:<a href=&quot;https://doi.org/10.1007/BF03189971&quot;>10.1007/BF03189971</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/1823870/&quot;>https://pubmed.ncbi.nlm.nih.gov/1823870</a></p></li><li><p>Ge, J, et al., &amp; Wen, AD (2015). Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects. <i>International journal of clinical pharmacology and therapeutics</i> 53(3) 272–276. DOI:<a href=&quot;https://doi.org/10.5414/CP202229&quot;>10.5414/CP202229</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25546165/&quot;>https://pubmed.ncbi.nlm.nih.gov/25546165</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end B01AC18;
